397 related articles for article (PubMed ID: 26048082)
1. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
2. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
3. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
4. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
5. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma].
Pu YQ; Zhang YP; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Nov; 41(11):869-875. PubMed ID: 38073220
[TBL] [Abstract][Full Text] [Related]
7. The Diagnosis of Pleural Tumors Other Than Mesothelioma.
Attanoos RL; Pugh MR
Arch Pathol Lab Med; 2018 Aug; 142(8):902-913. PubMed ID: 30040453
[TBL] [Abstract][Full Text] [Related]
8. Spindle cell tumors of the pleura: differential diagnosis.
Rdzanek M; Fresco R; Pass HI; Carbone M
Semin Diagn Pathol; 2006 Feb; 23(1):44-55. PubMed ID: 17044195
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
[TBL] [Abstract][Full Text] [Related]
10. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
Kao SC; Griggs K; Lee K; Armstrong N; Clarke S; Vardy J; van Zandwijk N; Burn J; McCaughan BC; Henderson DW; Klebe S
Pathology; 2011 Jun; 43(4):313-7. PubMed ID: 21532523
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
12. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
Hu Y; Yang Q; McMahon LA; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):411-3. PubMed ID: 20436345
[TBL] [Abstract][Full Text] [Related]
13. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
14. Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
Wagner D; Bourne PA; Yang Q; Goldman BI; Lewis JS; Xu H
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):301-7. PubMed ID: 18301236
[TBL] [Abstract][Full Text] [Related]
15. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
Tsuji S; Tsuura Y; Morohoshi T; Shinohara T; Oshita F; Yamada K; Kameda Y; Ohtsu T; Nakamura Y; Miyagi Y
Br J Cancer; 2010 Aug; 103(4):517-23. PubMed ID: 20628387
[TBL] [Abstract][Full Text] [Related]
16. Non-asbestos-related malignant pleural mesothelioma.
Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
[TBL] [Abstract][Full Text] [Related]
17. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
